Corante

About this Author
Derek Lowe
Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com

Chemistry and Pharma Blogs:
Pharmalot
Org Prep Daily
On Pharma
One in Ten Thousand
Away From the Bench
QDIS Blog
Chemical Musings
In Vivo Blog
The Chemblog
Molecule of the Day
Kinase Pro
Drugs and Poisons
Jungfreudlich
Chembark
Social Detritus
Pharmagossip
Whistling in the Wind
Organometallic Current
Great Molecular Crapshoot
Post Doc Ergo Propter Doc
A Chemist's Lab Notebook
The Curious Wavefunction Totally Synthetic
Pharma's Cutting Edge
The F- Blog
Synthetic Environment
Atom Pusher
Chemistry World Blog
Carbon-Based Curiosities
Eye on FDA
Hdreioplus
Closeted Chemistry
Chemical Forums
Curly Arrow
Power of Goo
Carbon Tet
Totally Medicinal
Sceptical Chymist
Lamentations on Chemistry
PeterMR
Mining Drugs
Regulatory Affairs of the Heart
Making Graphite Work
Liquid Carbon
Half-Decent Pharma Blog


Science Blogs and News:
The Loom
Uncertain Principles
The Crimson Canary
Fierce Biotech
Blogs for Industry
The Futile Cycle
Omics! Omics!
Young Female Scientist
Notional Slurry
Life of a Lab Rat
TP With Page Numbers
Nobel Intent
SciTech Daily
Is This Thing On?
Science Blog
Eastern Blot
Oncology Updates
FuturePundit
Flags and Lollipops
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Daily Biomed
Voyage to Arcturus
Adventures in Ethics and Science
Terra Sigillata
Transterrestrial Musings
The Mass Spectrometry Blog
Nodal Point
Slashdot Science
A Scientist's Life
Living the Scientific Life
John Johnson
Humans in Science
Tobias Sing's Bioinformatics Blog
Speculist
Science, Shrimp and Grits
Biopeer
Cosmic Variance
The Capsule
Zeroth Order Approximation
Science Library Blog
Biology News Net


Medical Blogs
MedPundit
Med Tech Sentinel
DB's Medical Rants
Dr. Charles
RangelMD
GruntDoc
The Health Care Blog
Cut to Cure
Respectful Insolence
Black Triangle
Diabetes Mine


Economics and Business
Marginal Revolution
Arnold Kling
The Volokh Conspiracy
Knowledge Problem
The Stalwart


Politics / Current Events
Virginia Postrel
Tinkerty Tonk
Instapundit
Asymmetrical Information
Belmont Club
Man Without Qualities
Belgravia Dispatch
Mickey Kaus
Colby Cosh
Progressive Reaction
No Watermelons


Belles Lettres
Two Blowhards
Critical Mass
Arts and Letters Daily
God of the Machine
Armavirumque
About Last Night
Just Released the 2008 Tribalization of Business study - an in-depth look at how 140+ organizations are managing and measuring online communities

In the Pipeline

« Problems and Solutions | Main | How Not to Do It: Sophomore Organic Edition »

January 15, 2007

Novo Nordisk Axes Med-Chem

Email This Entry

Posted by Derek

Here's one that I didn't see coming: Denmark's Novo Nordisk, a longtime major player in the field of diabetes, has decided to cut its small-molecule research completely. They're focusing on peptides and proteins instead. In a time when the big protein-based biotech companies (Amgen and Genentech) are trying to expand their small-molecule capabilities, Novo has decided to break the other way.

That Reuters article has various analysts talking about how this is no big surprise, that NN has never been that big in small molecules, etc. But I had a different impression. The company seemed to have a pretty good presence in many areas of diabetes research. If there was a good target to work on, you could generally count on them being in there, and they showed up in some of the less-trodden areas as well. Their patent and publication stream always looked quite strong, too.

Whether this is a trend, or the beginning of a trend, is a good question. I'm not at all convinced that it's cheaper to do protein therapies as opposed to small molecules (and it's not that I've heard anyone from Novo Nordisk making that argument, either). They must have seen more opportunities in their own biologics pipeline, and not had enough money to realize them if they kept working on the organic chemistry side of things. I'm not sure that this is a good long-term strategy, but they might be figuring that if they don't cut costs somewhere, there's not going to be a long term. So this might be specific to NN, or to companies of their size and financial standing. We shall see. . .

Comments (6) + TrackBacks (0) | Category: Business and Markets | Drug Industry History


COMMENTS

1. Morten on January 16, 2007 6:17 AM writes...

Well, Leo Pharma recently had their transgenic goats approved. That should bring down the price of recombinant protein production I think. Maybe that's what Novo is thinking.
Other than that I can't really think of any small molecule drugs from NN.
And size-wise you have to remember to include Novozymes as well.

Permalink to Comment

2. tom bartlett on January 16, 2007 8:56 AM writes...

My take on protein therapies-- and I've have the same opinion for nearly 20 years-- is that they can be terrific, but will never make up more than, say, 10-20% of the PDR. Small molecules have a lot going for them, and proteins, by their nature, need to be injectable and have a number of other thorny issues.

Permalink to Comment

3. Devices R Us on January 16, 2007 6:57 PM writes...

My take is that Novo might have been doing good chemistry but not making good oral drugs. They have only one (AFAIK) candidate in the clinic NN9101 and while they clearly are world class in the diabetes space, I am not sure they have ever been that good in the small molecule development, Prandin never really took off. On the other hand, they really do have the protein/peptide story down cold.

Permalink to Comment

4. SRC on January 16, 2007 8:51 PM writes...

Simplest explanation for the strategic disparity between Novo Nordisk and Amgen: stochastic management in action.

Permalink to Comment

5. Malapati. Ajay kumar on February 13, 2007 10:49 AM writes...

Dear sir,
I saw all ur personal and professional comments and interests. My hobbies and urs are very near. Thank god. I got u as a gift from got to good adviser about my career. I will be in contact with you forever.

Permalink to Comment

6. Ajay kumjar on February 13, 2007 11:10 AM writes...

I am very much interested in synthetic organic schemes as well as social service like planting, explaning consequences of rising population, clean and green. I think everybody should feel resposibility to maintain all these. I used to explain this as many people as I can.

Permalink to Comment

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
Pfizer's Prospects: Just Ducky
Happy Fourth of July
I Can Has Ugly Molecules?
More Pfizer Layoffs?
Leaving Comments: A Fix
The Gates Foundation: Dissatisfied With Results?
Another Alzheimer's Compound Goes Down
Unknown - But You Can Buy It